Reporting Adverse Events Linked to Your Implants

Adverse event reporting is supposed to help the health & safety regulators identify potential problems. Not enough reports were being made all the time PIP were being used. In the UK the MHRA say they have been and will continue to monitor adverse event reports from PIP women. Most women have no idea they are able to report adverse events linked with their implants. But if we dont report our bleeds, ruptures, our lymph node surgeries and symptoms the MHRA and the government will continue to ignore us and our symptoms. 

If you have experienced an adverse effect you associate with your PIP implants, please report them and ask your GP and/or surgeon to do the same. 

Lets do it everyone! Report Yours!  ♡

♥ Together we can make a difference!

In the UK Report Yours to MHRA using this link

https://www.gov.uk/report-problem-medicine-medical-device

In France report adverse events to ANSM

In Australia report adverse events to TGA
https://apps.tga.gov.au/prod/mdir/udir03.aspx

In Germany report adverse events to Bfarm

In the USA report adverse events to FDA

In Sweden report adverse events to MPA

Please refer to your Medical Devices Regulatory authority if your country is not shown here.

What? Chemicals in Implants? Are they SAFE?

What chemicals & what manufacturing procedures were used by PIP in manufacturing fraudulent implants? ANYONE KNOW?

Doctor Brawer in the USA says:

The Australian Regulator (TGA) did some tests on PIP

From TGA Australia

TGA on Cyclic Siloxanes D4, D5, D6

Presence of D4, D5 and D6 siloxanes
AFSSAPS noted that some batches of unauthorised gels contained higher amounts of small silicone molecules (called low molecular weight siloxanes) than the authorised gel. Thus, the TGA is testing the gels to determine the presence of D4, D5 and D6 siloxanes. Test results from GC-MS analyses indicate D4 is present in the gels of PIP breast implants at between 0 and 261ppm, with a median of 136ppm. D5 is present between 0-710ppm, with a median of 434ppm. D5 is present between 0 and 1005, with a median of 470ppm. There does not seem to be any relationship between the year of manufacture of the gel and the presence of D4, D5 and D6 siloxanes. These values could change with the testing of further samples.
Information provided by the suppliers of the raw materials, which were used to produce the gel used in PIP breast implants, together with more recent detailed information provided to the TGA by AFSSAPS, does suggest that the TGA findings are a reasonable estimate of the content of these siloxanes.

http://www.tga.gov.au/alert/pip-breast-implants-tga-update-2-april-2012

The SCENIHR report reproduced this table showing the concentrations of D4, D5 and D6

Published in SCENIHR 

EU Priorities for Health

SPEECH - 16 July 2015By COMMISSIONER 

Vytenis Andriukaitis

(2014-2019)Health & Food Safety

Speaking points on priorities for Health - European Policy Centre -

I have already said that on many occasions – a high level of health protection in all EU policies and activities is enshrined in the treaty. What does this mean in practice? For me it means that I need to strive for health to be included in all policy areas. I need to ensure that the Commission puts the health of European citizens first.
I personally made a commitment before the European Parliament to pursue Prevention, Promotion, and Protection in relation to health.